DiGA stands for Digitale Gesundheitsanwendungen, or digital health applications. It is a German reimbursement category created by the Digital Healthcare Act (Digitale-Versorgung-Gesetz) that allows certain software-based medical devices to be prescribed by doctors and reimbursed by statutory health insurance. To qualify, an application must be a low risk medical device under the MDR, meet requirements on data protection, security, and interoperability, and demonstrate a positive healthcare effect. BfArM operates a fast-track assessment and maintains the official DiGA directory of listed applications, which may be listed permanently or provisionally while evidence is gathered. The DiGA pathway has been closely watched internationally as one of the first national models for systematically reimbursing digital therapeutics, and several other countries have designed comparable schemes.
What is a DiGA?
A DiGA is a digital health application that can be prescribed and reimbursed by statutory health insurance in Germany.
Who approves DiGA in Germany?
BfArM, the Federal Institute for Drugs and Medical Devices, runs the DiGA fast-track assessment and maintains the official directory of reimbursable applications.
Dėl vaistinių preparatų tiekimo sutrikimo
Informuojame, kad laikinai sutriko šių vaistinių preparatų tiekimas Lietuvos Respublikos rinkai. NPAKID7 Vaistinio preparato pavadinimas Veiklioji medžiaga Stiprumas Farmacinė forma Kiekis pakuotėje Registruoto...
Lithuania VVKTNewΑνάκληση της παρτίδας 202412 του Καλλυντικού προϊόντος ALOHA Nails & Cosmetics REPAIR GEL MILKY LILAC, λόγω παρουσίας TPO
Αρ. πρωτ. 92834 Ανάκληση της παρτίδας 202412 του Καλλυντικού προϊόντος ALOHA Nails & Cosmetics REPAIR GEL MILKY LILAC, λόγω παρουσίας
Greece EOFNewDėl vaistinių preparatų tiekimo sutrikimo
Informuojame, kad laikinai sutriko šių vaistinių preparatų tiekimas Lietuvos Respublikos rinkai. NPAKID7 Vaistinio preparato pavadinimas Veiklioji medžiaga Stiprumas Farmacinė forma Kiekis pakuotėje Registruoto...
Lithuania VVKTWinrevair (sotatercept) | Relatório de avaliação de financiamento público disponível | Deferimento
Data : 13/07/2026
Portugal INFARMEDMedicamentos e calor: Cuidados essenciais para garantir a sua segurança e eficácia
Data : 18/07/2026
Portugal INFARMEDAz NNGYK indikáción túli gyógyszerrendelési ajánlást adott ki a tranexamic acid hatóanyagú gyógyszerekre
Az NNGYK indikáción túli gyógyszerrendelési ajánlásai link: tranexamic acid hatóanyagú gyógyszerek lokális és intraarticularis alkalmazásának intézményi szintű engedélyezése vérzéscsökkentés céljából or
Hungary NNGYKWest Nil Virus (WNV) – FrankreichNeu
West Nil Virus (WNV) – Frankreich Neu Sicherheitsinformation | Blut & Gewebe | 17.07.2026 Dem Bundesamt für Sicherheit im Gesundheitswesen (BASG) wurde von der französischen Behörde mitgete...
Austria BASG